Conclusions
ERCC1 expression, measured by IHC in pre-treatment tumor specimens, using a highly specific antibody, has limited clinical value in patients with advanced EOC treated with platinum and taxane based chemotherapy.
Highlights
► ERCC1 tumor expression in advanced EOC is not associated with patient survival.
► Common polymorphisms in ERCC1 were not associated with ERCC1 immunohistochemical expression.
► Common polymorphisms in ERCC1 were not associated with ERCC1 immunohistochemical expression.